Abbott Laboratories Launches Clinical Study of Early Heart Pump Intervention in Heart Failure

MT Newswires Live

Oct 24, 2024

Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.

The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.

Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.

Price: 116.66, Change: -0.35, Percent Change: -0.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2477656251"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477656251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477656251?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-24 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477656251","market":"fut","top_or_hot":-1,"title":"Abbott Laboratories Launches Clinical Study of Early Heart Pump Intervention in Heart Failure","media":"MT Newswires Live","content":"<html><body><p> Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.</p><p>The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.</p><p>Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.</p><p>Price: 116.66, Change: -0.35, Percent Change: -0.30</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott Laboratories Launches Clinical Study of Early Heart Pump Intervention in Heart Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott Laboratories Launches Clinical Study of Early Heart Pump Intervention in Heart Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-24 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.</p><p>The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.</p><p>Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.</p><p>Price: 116.66, Change: -0.35, Percent Change: -0.30</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477656251","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477656251","pubTimestamp":1729781727,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Abbott Laboratories  said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.Price: 116.66, Change: -0.35, Percent Change: -0.30","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","BK4566":"资本集团","BK4082":"医疗保健设备","BK4504":"桥水持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4592":"伊斯兰概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","BK4581":"高盛持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","ABT.AU":"Abundant Produce","BK4585":"ETF&股票定投概念","ABT":"雅培"},"translate_title":"雅培实验室启动心力衰竭早期心泵干预临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT.AU":1,"ABT":1},"content_text":"Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.Price: 116.66, Change: -0.35, Percent Change: -0.30","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}